Medication-induced labor with prostaglandins in viable fetuses: a 31-month retrospective study in the gynecology and obstetrics department of Amath Dansokho hospital/Kédougou/Senegal

Mouhamadou Wade; Marietou Thiam; Alexandre Oumar Seck; Yabbaba Moussa Gambo Aminatou; Fallou Diouf

doi:10.18203/2320-1770.ijrcog20260869

Authors

Mouhamadou Wade Department of Obstetrics and Gynecology, Amath Dansokho Regional Hospital, Kédougou, Senegal https://orcid.org/0000-0002-6102-6090
Marietou Thiam Faculty of Health Science, Iba Der Thiam University, Thies, Senegal
Alexandre Oumar Seck Faculty of Health Science, Iba Der Thiam University, Thies, Senegal
Yabbaba Moussa Gambo Aminatou Department of Obstetrics and Gynecology, Amath Dansokho Regional Hospital, Kédougou, Senegal
Fallou Diouf Department of Obstetrics and Gynecology, Amath Dansokho Regional Hospital, Kédougou, Senegal

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20260869

Keywords:

Senegal, Low-resource setting, Neonatal outcomes, Maternal outcomes, Cesarean section, Labor induction, Prostaglandins, Misoprostol

Abstract

Background: To analyze the indications, methods, and outcomes of labor induction with prostaglandins at the Gynecology and Obstetrics Department of Amath Dansokho Regional Hospital in Kédougou, Senegal.

Methods: We conducted a retrospective cohort study including 2,750 deliveries from January 1, 2023, to July 31, 2025. All pregnant women ≥28 weeks receiving prostaglandin-induced labor were included (n=501). Exclusion criteria were intrauterine fetal death, abnormal fetal heart rate on admission, prophylactic cesarean, and incomplete records. Data on sociodemographic, obstetric history, induction indications, induction method, and maternal and neonatal outcomes were analyzed using SPSS 27. Patients were classified as “Exposed” (induced) and “Unexposed” (spontaneous labor).

Results: Labor induction frequency was 18.2%. Main indications were post-term pregnancy (29.4%), hypertensive disorders (28.9%), and preventive induction (19.3%). Misoprostol (91.6%) was the primary induction agent, administered vaginally at 25 µg per dose. Induction success was 97.6%. Vaginal delivery occurred in 85% of induced patients, and cesarean section risk was significantly lower compared to spontaneous labor (14.8% vs. 25.9%; RR=0.57, p<0.001). Uterine rupture occurred in 0.6% of cases. Neonatal outcomes, including Apgar score <7 at 5 minutes, neonatal resuscitation, transfer, and stillbirth, did not differ significantly between groups.

Conclusions: Labor induction with prostaglandins is a safe and effective strategy in a resource-limited and geographically isolated setting, reducing cesarean section rates without compromising neonatal outcomes. Preventive induction and structured monitoring protocols are practical approaches to improve maternal and neonatal safety in low-resource contexts. These findings support the use of context-specific guidelines and further research on optimal induction protocols in similar settings.

Metrics

Metrics Loading ...

References

Berland M. le declenchement artificiel du travail. In: Encyclopedie de medecine Chirurgie obstétrique. 1987;12.

CNGOF. Déclenchement du travail : recommandations pour la pratique clinique. Gynécol Obstét Fertil Senol. 2018;46(2):94‑104.

Duvillier C, Gams J, Rousseau A, Rozenberg P. Induction du travail par misoprostol oral versus misoprostol vaginal : étude avant-après. Gynécol Obstet Fertil Senol. 2022;50(6):475‑80. DOI: https://doi.org/10.1016/j.gofs.2022.01.008

Keirse MJNC. Prostaglandins in labour induction. Baillière’s Clin Obstet Gynaecol. 1993;7(2):293-307.

Blanc‑Petitjean P, Salomé M, Dupont C, Crenn‑Hebert C, Gaudineau A, Perrotte F, et al. Résultats de la cohorte prospective en population MEDIPE état des lieux des pratiques de déclenchement en France. Gynecol Obstet Fertil Senol. 2019;47(8):555-61. DOI: https://doi.org/10.1016/j.gofs.2019.05.002

Wade AM. Déclenchement artificiel du travail sur enfant vivant : techniques, indications et résultats. Dakar,Sénégal: Université Cheikh Anta DIOP. 2021.

Dolo M. Déclenchement artificiel du travail d’accouchement : utilisation du misoprostol dans la maternité du centre de sante de référence de la commune v. Bamako, Mali. 2010.

Deneux-Tharaux C, Carmona E, Bouvier-Colle MH, Breart G. Mortalité maternelle en France. BEH. 2006;50:392‑402.

Coulibaly A. Déclenchement artificiel du travail d’accouchement : utilisation du misoprostol (pronostic maternel et fœtal) au centre de sante de référence de la commune I du district de Bamako. (Bamako, Mali): Bamako, Mali. 2019.

Ezechi OC, Kalu BKE, Njokanma FO, Nwokoro CA, Okeke GCE. Vaginal misoprostol induction of labour: a Nigerian hospital experience. J Obstet Gynaecol. 2004;24(3):239-42. DOI: https://doi.org/10.1080/01443610410001660698

World Health Organization. WHO Model List of Essential Medicines. Geneva: World Health Organization; 2023. Available at: https://iris.who.int/handle/10665/371090. Accessed on 11 January 2026.

Morris JL, Winikoff B, Dabash R, Weeks A, Faundes A, Gemzell-Danielsson K, et al. FIGO’s updated recommendations for misoprostol used alone in gynecology and obstetrics. Int J Gynecol Obstet. 2017;138(3):363‑6. DOI: https://doi.org/10.1002/ijgo.12181

Feitosa FE, Sampaio ZS, Alencar CA, Amorim MM, Passini R. Sublingual vs. vaginal misoprostol for induction of labor. Int J Gynaecol Obstet. 2006;94(2):91-5. DOI: https://doi.org/10.1016/j.ijgo.2006.04.031

Bartusevicius A, Barcaite E, Krikstolaitis R, Gintautas V, Nadisauskiene R. Sublingual compared with vaginal misoprostol for labour induction at term: a randomised controlled trial. BJOG. 2006;113(11):1431-6. DOI: https://doi.org/10.1111/j.1471-0528.2006.01108.x

Gaudineau A, Vayssière C. Maturation cervicale par misoprostol sur foetus viable. J Gynécologie Obstétrique Biol Reprod. 2014;43(2):169‑78. DOI: https://doi.org/10.1016/j.jgyn.2013.11.010

Hannah ME, Hannah WJ, Hewson SA, Hodnett ED, Saigal S, Willan AR. Planned caesarean section versus planned vaginal birth for breech presentation at term: a randomised multicentre trial. Lancet. 2000;356(9239):1375-83. DOI: https://doi.org/10.1016/S0140-6736(00)02840-3

Rojansky N, Tsafrir A, Ophir E, Ezra Y. Induction of labor in breech presentation. Int J Gynecol Obstet. 2001;74(2):151‑6. DOI: https://doi.org/10.1016/S0020-7292(01)00424-6

Gueye M, Hoballah A, Hage Ali H, Wade FK, Biaye D, Gning HM, et al. Safety of Misoprostol in Labor In- duction for Twin Pregnancies: A Systematic Review. Open J Obstet Gynecol. 2025;15:789-805. DOI: https://doi.org/10.4236/ojog.2025.154065

Tenson D, Wallström T, Sjöstrand M, Åkerud H, Gemzell‑Danielsson K, Wiberg‑Itzel E. Induction of labor in women with a uterine scar. J Matern-Fetal Neonatal Med. 2015;29(20):3286‑91.

Cogan A, Barlow P, Benali N, Murillo D, Manigart Y, Belhomme J, et al. An audit about labour induction, using prostaglandin, in women with a scarred uterus. Arch Gynecol Obstet. 2012;286(6):1399‑406. DOI: https://doi.org/10.1007/s00404-012-2481-5

Dupont C, Carayol M, Le Ray C, Barasinski C, Beranger R, Burguet A, et al. Recommandations pour l’administration d’ocytocine au cours du travail spontanée. Texte court des recommandations. Gynecol Obstet Fertil Senol. 2017;45(1):56-61. DOI: https://doi.org/10.1016/j.gofs.2016.12.017

Caughey AB, Sundaram V, Kaimal AJ, Cheng YW, Gienger A, Little SE, et al. Maternal and neonatal outcomes of elective induction of labor. Evid Rep Technol Assess. 2009;176:1‑257.

Winer N. Modalité du déclenchement dans les grossesses prolongées. J Gynecologie Obstétrique biol reprod. 2011;40(8):796‑811. DOI: https://doi.org/10.1016/j.jgyn.2011.09.021

Haute Autorité de Santé (HAS), Service des bonnes pratiques professionnelles et Service évaluation économique et santé publique : Déclenchement artificiel du travail à partir de 37 semaines d’aménorrhée. 2008. Available at: https://www.has‑sante.fr/jcms/c_666473/en/declenchement‑artificiel‑du‑travail‑a‑partir‑de‑37‑semaines‑d‑amenorrhee. Accessed on 11 January 2026.

Ndiaye MD. Déclenchement artificiel du travail sur utérus cicatriciel : évaluation de l’efficacité et de l’innocuité du misoprostol, de la sonde de foley et du syntocinon. Dakar, Sénégal: Cheikh Anta DIOP. 2013.

Helmig RB, Hvidman LE. An audit of oral administration of Angusta1 (misoprostol) 25mg for induction of labor in 976 consecutive women with a singleton pregnancy in a university hospital in Denmark. Acta OGS. 2020;99(10):1396-402. DOI: https://doi.org/10.1111/aogs.13876

Dekker GA, Chan A, Luke CG, Priest K, Riley M, Halliday JF, et al. Risk of uterine rupture in Australian women attempting vaginal birth after prior caesarian section: a retrospective population-based cohort study. BJOG. 2010;117(11):1358‑65. DOI: https://doi.org/10.1111/j.1471-0528.2010.02688.x

Lydon‑Rochelle M, Holt VL, Easterling TR, Martin DP. Risk of rupture during labor among women with a prior cesarean delivery. N Engl J Med. 2001;345(1):3‑8. DOI: https://doi.org/10.1056/NEJM200107053450101

Grobman WA, Lai Y, Landon MB, Spong CY, Leveno KJ, Rouse DJ, et al. Outcomes of induction of labor after one prior cesarean. Obstete41e` Gynecol. 2007;109(2):262‑9. DOI: https://doi.org/10.1097/01.AOG.0000254169.49346.e9